

# Hyphens Pharma International Limited


Date: 17 March 2021

**BUY**  
**(Maintained)**

**Target Price: S\$0.370**  
**(+19.4%)**

**HYP SP**

**Price: S\$0.310** (as at 16 March 2021)



Share price	1M	3M	6M	1Y
Hyphens Pharma	-6.1%	+3.3%	-21.5%	+63.2%
Catalist Index	-2.8%	+7.6%	+10.4%	+61.1%

<b>Market Capitalisation</b>	S\$93.1 million
<b>Current Price</b>	S\$0.310
<b>Shares Outstanding</b>	300.4 million
<b>Free Float</b>	22.0%
<b>Major Shareholder</b>	Inomed Holding Pte Ltd 39.9% Tan Kia King 25.4% Tan Chwee Choon 12.7%
<b>Recommendation of other brokers</b>	1 Neutral 1 Accumulate

Source: Company data, Bloomberg, SAC Capital

## Analyst

Lim Li Jun Tracy +65 6232 3239  
[tljm@saccapital.com.sg](mailto:tljm@saccapital.com.sg)

## Analyst

Lam Wang Kwan +65 6232 3237  
[lamwk@saccapital.com.sg](mailto:lamwk@saccapital.com.sg)

## Growing regional presence

**FY2020 revenue grew but net profit hurt by higher provisions.** Revenue rose 3.6% yoy to S\$123.7m, driven by 25.9% increase in sales of the proprietary brands products. However, net profit fell 5.6% to S\$6.2m, after higher allowance for inventory obsolescence (S\$1.6m) and higher advertising expenses (S\$1.6m), offset by increase in government grants for job support (S\$1.7m).

**Proprietary brands products were the key revenue driver.** Albeit being the smallest of the three business segments (14.7% of total sales), proprietary brands was the key revenue growth driver (up 25.9%), with higher demand for dermatological products under Ceradan brand and nutritional supplements under Ocean Health brand. Hyphens also expanded its overseas footprint, through the distribution of Ocean Health in Sri Lanka, Ceradan in China, and TDF Fairence in South Korea.

**Marginal adjustments to our earnings estimates.** We lowered our revenue estimates marginally (FY2021E -2.9%, FY2022E -2.8%) to reflect slower sales as COVID-induced buying eases with the rollout of vaccines. However, we remained optimistic on the potential of the proprietary products and their penetration into new markets.

We have raised our earnings estimates slightly (FY2021E +8.7%, FY2022E 0.0%) to factor in the benefit of the extension of job support scheme, and lower distribution and administrative expenses than our previous forecast. In addition, FY2023E estimates are introduced, which reflect 3.1% and 3.8% yoy growth for revenue and net profit respectively.

**Maintain BUY but at lower fair value of S\$0.37 (from S\$0.39).** Our DCF-derived target price translates into a FY21E P/E of 18.3x.


**Key Risks:** Product differentiation, foreign exchange uncertainty, supply chain disruption.

## Key Financials

Year ended 31 Dec (S\$'000)	FY2019A	FY2020A	FY2021E	FY2022E	FY2023E
<b>Revenue</b>	119,442	123,698	130,150	134,200	138,395
<b>% change</b>	-1.2%	3.6%	5.2%	3.1%	3.1%
<b>Profit/(loss) before tax</b>	7,987	7,108	7,339	7,785	8,084
<b>Pretax margin</b>	6.7%	5.7%	5.6%	5.8%	5.8%
<b>Net profit</b>	6,530	6,163	6,069	6,438	6,685
<b>EPS (S cents)</b>	2.17	2.05	2.02	2.14	2.23
<b>P/E (x)</b>	14.3	15.1	15.3	14.5	13.9
<b>P/B (x)</b>	2.1	2.0	1.8	1.7	1.6
<b>Net Debt/Equity (%)</b>	Net Cash				

## Investment Highlights

### FY2020 Revenue



- Specialty Pharma Principals
- Proprietary Brands
- Medical Hypermart & Digital

Source: Company Data, SAC Capital

### Business Overview:

Hyphens Pharma International Limited is primarily engaged in the marketing, distribution and sales of specialty pharmaceutical products in countries in the ASEAN region. The Group also develops and sells a range of proprietary dermatological and health supplement products, which fall under its Proprietary Brands business segment. The Group's wholly owned subsidiary Pan Malayan is a wholesale provider of pharmaceutical and medical supplies in Singapore.

### Higher provisions dragged profits down

FY2020 revenue increased 3.6% yoy, but NPAT declined 5.6% due to higher provisions and distribution costs. Topline increased by 3.6% yoy from S\$119.4 million in FY2019 to S\$123.7 million in FY2020, mainly due to higher sales from the proprietary brands segment which grew by 25.9% with a higher demand for dermatological products under the Ceradan brand and nutritional supplements under Ocean Health brand. Gross profit margin for FY2020 remained relatively stable at 35.4% (FY2019: 35.7%).

However, the bottomline saw a yoy decline due to higher allowance for inventory obsolescence and higher advertising and promotional expenses to promote products in proprietary brands and specialty pharma principals segments. Hyphens' net profit decreased by 5.6% from S\$6.5 million in FY2019 to S\$6.2 million in FY2020.

### Other Losses

Hyphens' one-off losses include a charge of S\$1.6 million for the provision for inventory obsolescences. Provision was charged on 1) specialty pharma inventory with weaker demand from the lockdown in the Philippines (S\$0.2m) and overall inventory (S\$0.1m); 2) at medical hypermart for short shelf-life items such as flu vaccines (S\$0.2m); 3) write down of personal protective equipment (PPE) to net realisable value in view of higher supply in the market (S\$0.6m); and 4) Covid-19 diagnostic test kits (S\$0.5m).

With the extension of the government's Jobs Support Scheme (JSS) by 6 months to September 2021, Hyphens will continue to benefit from the government grants, although we expect lower grants in FY2021 compared to FY2020.

We expect topline to continue to increase from higher sales in the proprietary brands segment and penetration into new markets. We also expect that the advertising and promotional expenses budget to continue to rise in FY2021 as they bring their products to more markets.

### E-pharmacy licence awarded

Hyphens has been awarded an e-pharmacy licence for WellAway Pharmacy in 2020 by the Health Sciences Authority in Singapore. WellAway Pharmacy is a healthcare service delivery, which delivers the medicine to patients after remote diagnosis and treatment, or telemedicine service. WellAway aims to leverage on the medical and logistical expertise of Pan-Malayan, to work closely with medical clinics in Singapore.

### **Increasing focus on Proprietary Brands**

Revenue from proprietary brands segment rose 25.9% yoy, from S\$14.5 million to S\$18.2 million. This was due to higher demand for dermatological products under Ceradan brand and nutritional supplements under Ocean Health brand.

Hyphens is placing more focus on its proprietary brands segment, with higher R&D costs incurred, growing 110.7% yoy from S\$0.2 million to S\$0.4 million. We believe this is just the start of higher R&D investment into the segment as it shifts its focus to building core brands and increase outreach.

In line with this, Hyphens expanded its proprietary brands footprint overseas, namely the distribution of Ocean Health into Sri Lanka, Ceradan into Mainland China, and TDF Fairence into South Korea. This is a step forward to tap into bigger markets outside Southeast Asia. In FY2020, sales contribution from proprietary brands make up 14.7% of total revenue (FY2019: 12.1%). Although we do not expect high increase in their sales contribution in the short term, as brand and recognition and loyalty take time to build, we believe these ventures are strategic in the long-term.

We expect administrative expenses to increase yoy with increased R&D costs for the next few periods in their bid to grow their proprietary brands segment. In addition, we expect distribution costs to increase with higher advertising and promotional expenses in their new markets.

As these products are developed, marketed and sold by Hyphens, gross margins from the proprietary brands segment is the highest out of the three segments.

### **Marginal adjustments to our earnings estimates**

We lowered our revenue estimates marginally (FY2021E -2.9%, FY2022E -2.8%) to reflect slower sales as COVID-induced buying eases with the rollout of vaccines. However, we remained optimistic on the potential of the proprietary products and their penetration into new markets.


We have raised our earnings estimates slightly (FY2021E +8.7%, FY2022E 0.0%) to factor in the benefit of the extension of job support scheme, and lower distribution and administrative expenses. In addition, FY2023E estimates are introduced, which reflect 3.1% and 3.8% yoy growth for revenue and net profit respectively.

### **Maintain BUY rating at lower target price of S\$0.37**

We maintain a BUY rating on Hyphens Pharma, but lower fair value to S\$0.37 (from S\$0.39). Our DCF-derived target price translates into a FY21E P/E of 18.3x. Our target price implies a 19.4% upside.

## Business Segments

FY2020 Revenue



- Specialty Pharma Principals
- Proprietary Brands
- Medical Hypermart & Digital

Source: Company Data, SAC Capital

Hyphens is a leading specialty pharmaceutical and consumer healthcare group with a diverse geographical footprint. The Group's primary business is the marketing and sale of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorships or licensing and supply agreements with brand principals. In addition, the Group develops, markets and sells its range of proprietary dermatological and health supplements under its Proprietary Brands segment, and also engages in the wholesale of pharmaceuticals and medical supplies in Singapore through wholly-owned subsidiary Pan Malayan Pharmaceuticals Pte Ltd.

The Group's businesses can be categorised into 3 segments:

- a) Specialty Pharma Principals
- b) Proprietary Brands
- c) Medical Hypermart and Digital

### Specialty Pharma Principals



\*Selected Principals

Source: Company Data

Hyphens markets and distributes specialty pharmaceutical products in ASEAN through distributorship or licensing agreements with brand principals mainly from Europe and the United States. Its core expertise is in the field of dermatology, pediatrics and neonatology, allergy, cardiology and radiology.


### Proprietary Brands



Source: Company Data

The Group's proprietary products are mainly dermatological products and health supplements. Launched in 2011, Ceradan® was the first product, which is a dermatological product targeted at eczema patients. It has extended the range to include TDF, a line of dermo-cosmetic products, and Ocean Health® for health supplements, through the acquisition of Ocean Health® Singapore in 2016. Ceradan® Advanced was launched in July 2019. The procurement of CG 210 hair-loss product line in August 2020 makes it the latest addition to the Group's proprietary brands products.

## Medical Hypermart and Digital



The Medical Hypermart is an online B2B platform for the wholesale of pharmaceutical and medical supplies in Singapore. It leverages on the network and industry presence of Pan Malayan, which has been operating in this business segment since late 1940s. Users of the platform include healthcare professionals, healthcare institutions and retail pharmacies. The platform also enables brand principals to publish product information and educational material that will raise awareness and brand profile among the medical professionals.

### Geographical Footprint

The Group has a direct presence in Singapore, Indonesia, Malaysia, Philippines and Vietnam, as well as marketing and distribution networks in Bangladesh, Brunei, Cambodia, Hong Kong, Myanmar and Oman. With the partnership with SUTL HK, the Group seeks to target the markets in Hong Kong Special Administrative Region (“HK SAR”), Macau and Duty-Free Channels in China. In addition, Hyphens expanded Ocean Health distribution into Sri Lanka, and Ceradan into Mainland China in 2HFY20.

## Income Statement

\$'000	Fiscal Year Ended 31 Dec				
	FY2019A	FY2020A	FY2021E	FY2022E	FY2023E
<b>Revenue</b>	<b>119,442</b>	<b>123,698</b>	<b>130,150</b>	<b>134,200</b>	<b>138,395</b>
Cost of sales	(76,773)	(79,939)	(85,354)	(87,271)	(90,227)
<b>Gross profit</b>	<b>42,669</b>	<b>43,759</b>	<b>44,796</b>	<b>46,929</b>	<b>48,168</b>
Interest Income	157	180	72	94	94
Other income and gains	389	2,248	1,000	427	427
Distribution costs	(24,837)	(26,523)	(27,592)	(28,048)	(28,371)
Administrative expenses	(9,772)	(10,138)	(10,153)	(10,845)	(11,455)
Finance costs	(138)	(110)	(110)	(110)	(110)
Other losses	(481)	(2,128)	(675)	(663)	(669)
<b>Profit before tax from continuing operations</b>	<b>7,987</b>	<b>7,108</b>	<b>7,339</b>	<b>7,785</b>	<b>8,084</b>
Income tax expense	(1,457)	(945)	(1,270)	(1,347)	(1,398.5)
<b>Profit, net of tax</b>	<b>6,530</b>	<b>6,163</b>	<b>6,069</b>	<b>6,438</b>	<b>6,685</b>
Earnings Per Share (cents)					
Basic and Diluted	2.17	2.05	2.02	2.14	2.23

## Balance Sheet

(\$S'000)	Fiscal Year Ended 31 Dec				
	FY2019A	FY2020A	FY2021E	FY2022E	FY2023E
Plant and equipment	5,948	4,807	4,790	4,712	4,986
Intangible assets	7,462	7,890	8,036	7,940	7,910
Deferred tax assets	105	47	47	47	47
<b>Total non-current assets</b>	<b>13,515</b>	<b>12,744</b>	<b>12,873</b>	<b>12,699</b>	<b>12,944</b>
Inventories	11,431	16,888	12,393	12,671	13,100
Trade and other receivables	28,654	29,421	31,865	32,857	33,884
Prepayments	366	564	564	564	564
Cash and cash equivalents	26,165	27,526	34,347	37,979	42,253
<b>Total current assets</b>	<b>66,616</b>	<b>74,399</b>	<b>79,169</b>	<b>84,070</b>	<b>89,801</b>
<b>Total assets</b>	<b>80,131</b>	<b>87,143</b>	<b>92,042</b>	<b>96,770</b>	<b>102,745</b>
Share capital	32,641	32,641	32,641	32,641	32,641
Retained earnings	26,467	29,626	33,442	37,206	41,542
Other reserves	(15,032)	(15,092)	(15,092)	(15,092)	(15,092)
<b>Total equity</b>	<b>44,076</b>	<b>47,175</b>	<b>50,991</b>	<b>54,755</b>	<b>59,091</b>
Deferred tax liabilities	469	409	409	409	409
Lease liabilities, non-current	2,442	3,558	3,558	3,558	3,558
<b>Total non-current liabilities</b>	<b>2,911</b>	<b>3,967</b>	<b>3,967</b>	<b>3,967</b>	<b>3,967</b>
Income tax payable	1,459	1,345	1,270	1,347	1,399
Trade and other payables	30,628	33,240	35,815	36,701	38,289
Lease liabilities, current	757	-	-	-	-
Other financial liabilities, current	1,057	1,416	-	-	-
<b>Total current liabilities</b>	<b>33,144</b>	<b>36,001</b>	<b>37,085</b>	<b>38,048</b>	<b>39,687</b>
<b>Total liabilities</b>	<b>36,055</b>	<b>39,968</b>	<b>41,052</b>	<b>42,015</b>	<b>43,654</b>
<b>Total equity and liabilities</b>	<b>80,131</b>	<b>87,143</b>	<b>92,042</b>	<b>96,769</b>	<b>102,745</b>

## Ratios

	Fiscal Year Ended 31 Dec				
	FY2019A	FY2020A	FY2021E	FY2022E	FY2023E
<i>Adoption of SFRS 16 Leases increased lease liability in FY2019</i>					
<b>Profitability (%)</b>					
Gross profit/(loss) margin	35.7%	35.4%	34.4%	35.0%	34.8%
Profit/(loss) before tax margin	6.7%	5.7%	5.6%	5.8%	5.8%
<b>Liquidity (x)</b>					
Current ratio	2.0	2.1	2.1	2.2	2.3
Quick ratio	1.7	1.6	1.8	1.9	1.9
Interest coverage ratio	58.9	65.6	67.7	71.8	74.5
Net Debt to Equity	Net Cash	Net Cash	Net Cash	Net Cash	Net Cash
<b>Valuation (x)</b>					
P/S	0.8	0.8	0.7	0.7	0.7
P/E	14.3	15.1	15.3	14.5	13.9
Core P/E at target price	17.0	18.0	18.3	17.3	16.6
P/B	2.1	2.0	1.8	1.7	1.6
P/NTA	2.5	2.4	2.2	2.0	1.8
<b>Cash Conversion Cycle</b>					
Trade receivable days	89	86	86	88	88
Inventory days	54	77	53	53	53
Trade payable days	144	144	143	142	142
CCC days	0	18	-4	-1	-1

## Cash Flows Statement

(\$S'000)	Fiscal Year Ended 31 Dec				
	FY2019A	FY2020A	FY2021E	FY2022E	FY2023E
<b>Profit/(loss) before tax</b>	<b>7,987</b>	<b>7,108</b>	<b>7,339</b>	<b>7,785</b>	<b>8,084</b>
Amortisation of intangible assets	406	401	401	401	401
Depreciation of plant and equipment	1,599	1,680	1,703	1,892	2,250
Changes in working capital	935	(3,810)	2,502	(513)	(289)
Others	(157)	(180)	(72)	(94)	(94)
<b>Net cashflows from operating activities</b>	<b>9,453</b>	<b>4,130</b>	<b>10,736</b>	<b>8,207</b>	<b>9,036</b>
Purchase of plant and equipment	(502)	(371)	(1,500)	(2,000)	(1,700)
Purchase of intangible assets	(104)	(829)	(253)	(306)	(371)
Interest received	157	180	72	94	94
<b>Net cash flows used in investing activities</b>	<b>-449</b>	<b>-1,013</b>	<b>-1,681</b>	<b>-2,212</b>	<b>-1,978</b>
Gross proceeds from IPO	-	-	-	-	-
Dividends paid to equity owners	(1,650)	(3,004)	(2,124)	(2,253)	(2,674)
Repayment of borrowings	(2,700)	-	-	-	-
Proceeds from borrowings	-	-	-	-	-
Others	(842)	1,249	(110)	(110)	(110)
<b>Net cash flows from (used in) financing activities</b>	<b>(5,192)</b>	<b>(1,755)</b>	<b>(2,234)</b>	<b>(2,363)</b>	<b>(2,784)</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>3,812</b>	<b>1,361</b>	<b>6,821</b>	<b>3,631</b>	<b>4,275</b>
Cash and cash equivalents at beginning	22,353	26,165	27,526	34,347	37,979
<b>Cash and cash equivalents, ending balance</b>	<b>26,165</b>	<b>27,526</b>	<b>34,347</b>	<b>37,979</b>	<b>42,253</b>

**DISCLAIMERS AND DISCLOSURES**

This report has been prepared and distributed by SAC Capital Private Limited (“**SAC Capital**”) which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report has been prepared for the purpose of general circulation, we have not had regard to the specific investment objectives, financial situation, tax position or unique needs and constraints of any individual person or any specific group of persons and does not purport to be comprehensive or contain all necessary information which a prospective investor may require in arriving at an investment decision. Any prospective purchaser should make his own investigation of the securities and all information provided. Advice should be sought from a financial adviser regarding suitability, taking into account the specific investment objectives, financial situation or particular needs of the person in receipt of the recommendation, before a commitment to purchase is entered into.

This report does not constitute or form part of any offer or solicitation of any offer to buy or sell any securities. This report is confidential and the information in this report shall not be copied or reproduced in part or in whole, and save for the recipient of this report, shall not be disclosed to any other person without the prior written consent of SAC Capital. The distribution of this report outside the jurisdiction of Singapore is also strictly prohibited.

Whereas SAC Capital has not independently verified all the information set out in this report, all reasonable care and effort has been taken to ensure that the facts stated herein are accurate, this report might contain certain forward looking statements and forward looking financial information which are based on certain assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results or performance of the subject company to be materially different from those expressed herein. Predictions, projections or forecasts of the economy or market trends are not indicative of the future performance of the subject company. The inclusion of such statements and information should not be regarded as a representation, warranty or prediction with respect to the accuracy of the underlying assumptions of the subject company or that the forecast results will or are likely to be achieved.

Our opinion and facts set out in this report are based on the market, economic, industry and other applicable conditions prevailing as at the date of the preparation of this report. Such conditions may change significantly over a relatively short period of time and we assume no responsibility to update, revise or reaffirm our opinion in light of any development subsequent to the publication of this report, that may or may not have affected our opinion contained herein.

This report contains forward-looking statement which are based on assumptions or forecasts and are subject to uncertainties which may result in the actual result or performance to be materially different from the opinion or facts set out herein. Caution should be exercised in placing undue reliance on such statements. such assumptions or forecasts may change over a relatively short period of time and we assume no responsibility to update, revise or reaffirm our opinion in light of any development subsequent to the publication of this report.

No representation or warranty, expressed or implied, is made and no responsibility is accepted by the company, SAC Capital, or any of their affiliates, advisers or representatives as to the fairness, accuracy, completeness or adequacy of such information or facts, in this report or any other written or oral information made available to any interested party or its advisers and any liability therefore is hereby expressly disclaimed.

SAC Capital and its associates, directors, and/or employees may have positions in the securities covered in the report and may also perform or seek to perform other corporate finance and/or capital markets related services for the company whose securities are covered in the report. SAC Capital and its related companies may from time to time perform advisory services or solicit such advisory services from the entity mentioned in this report (“**Other Services**”). This report is therefore classified as a non-independent report. However, the research professionals involved in the preparation of this report are independent of those possible or actual business relationships as they have not and will not participate in the solicitation or provision of such business.

As at the date of this report, SAC Capital does not have proprietary positions or interests in the subject company, except for:

Party	Quantum of position
Nil	Nil

As at the date of this report, SAC Capital, has had business relations with the subject company within the past 12 months, as disclosed hereunder:

Nature of Business Relation	Date of Business Relation
Nil	Nil

As at the date of this report, none of the analysts who covered the securities in this report have any proprietary position or material interest in the subject companies covered here in, except for:

<b>Analyst name</b>	<b>Quantum of position</b>
Nil	Nil

**ANALYST CERTIFICATION/REGULATION AC**

As noted above, research analyst(s) of SAC Capital who produced this report hereby certify that

- (i) The views expressed in this report accurately reflect his/her personal views about the subject corporation(s);
- (ii) The report was produced independently by him/her;
- (iii) He/she does not on behalf of SAC Capital or any other person carry out Other Services involving any of the subject corporation(s) or securities referred to in this report; and
- (iv) He/she has not received and will not receive any compensation directly or indirectly related to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. He/she has not and will not receive any compensation directly or indirectly linked to the performance of the securities of the subject corporation(s) from the time of the publication of this report either.